ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Exercise inhibits proliferation and induces apoptosis of lung adenocarcinoma cells via the POU2F2-SPOCD1-PI3K/AKT signaling axis.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung adenocarcinoma (LUAD) is a prevalent and deadly form of lung cancer. Exercise has been shown to inhibit LUAD progression, yet the underlying molecular mechanisms remain unclear. The transcription factor POU2F2 has been implicated in LUAD tumorigenesis, but its precise role and regulatory targets have not been fully elucidated.
methodsPOU2F2 expression in LUAD cell lines (HCC4006, Calu-3, NCI-H2009) and normal lung epithelial cells (BEAS-2B) was assessed by qRT-PCR and Western blot. Functional assays (CCK-8, EdU, flow cytometry, TUNEL) were performed following shRNA-mediated knockdown of POU2F2 or SPOCD1 and upregulation of POU2F2. Mechanistic studies included bioinformatics, dual-luciferase assay, ChIP, DNA pull-down, and Western blot. In vivo tumor growth was evaluated via xenograft models with Ki67 IHC.
resultsExercise suppressed POU2F2 expression, which was otherwise elevated in LUAD cells. Knockdown of POU2F2 or its downstream target SPOCD1 reduced proliferation and increased apoptosis. Mechanistically, POU2F2 directly bound to and activated the SPOCD1 promoter, thereby enhancing PI3K/AKT pathway signaling. Rescue experiments confirmed that SPOCD1 mediates POU2F2's oncogenic effects. In vivo, POU2F2 knockdown inhibited tumor growth and Ki67 expression.
conclusionsExercise suppresses LUAD progression by downregulating POU2F2, thereby disrupting the POU2F2-SPOCD1-PI3K/AKT axis. This pathway plays a critical role in LUAD cell survival and may serve as a promising therapeutic target. KEY POINTS: Exercise inhibits LUAD progression by downregulating the oncogenic transcription factor POU2F2. The POU2F2-SPOCD1 axis exerts its oncogenic function by activating the PI3K/AKT pathway. The POU2F2-SPOCD1 axis may represent a promising therapeutic target for LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.